Is there a place for optimizing thoracic radiotherapy in limited-stage small cell lung cancer after twenty years?

Thoracic radiotherapy (TRT) is one of the main treatments in limited-stage small cell lung cancer (LS-SCLC). Hyperfractionated TRT (45 Gy, 1.5 Gy twice daily) has been the standard of care (SOC) since Turrisi and colleagues published the results of their clinical trial in 1999. Two meta-analyses hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Barros, José Máximo, Rizzo, Manglio Miguel, Chiozza, Jorge Oscar, Couñago, Felipe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829628/
https://www.ncbi.nlm.nih.gov/pubmed/33552934
http://dx.doi.org/10.5306/wjco.v12.i1.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829628/
https://www.ncbi.nlm.nih.gov/pubmed/33552934
http://dx.doi.org/10.5306/wjco.v12.i1.1

Ejemplares similares